HOLON, Israel, Oct. 29,
2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq:
CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company
and a pioneer in computational target discovery, today announced,
that it will release its third quarter 2024 financial results on
Tuesday, November 12, 2024, before
the U.S. financial markets open. Management will host a conference
call and webcast to review the financial results and provide a
corporate update at 8:30 am ET.
As part of the update, management will discuss Compugen's data
that will have been presented at the Annual Meeting of the Society
for Immunotherapy of Cancer, being held on November 8-10, 2024.
To access the live conference call by telephone, please dial
1-866-744-5399 from the U.S.,
or +972-3-918-0644 internationally. The call will be available via
live webcast through Compugen's website, located at the following
link.
Following the live webcast, a replay will be available on the
Company's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery platform (Unigen™) to identify new drug
targets and biological pathways for developing
cancer immunotherapies. Compugen has two proprietary
product candidates in Phase 1 development: COM701, a potential
first-in-class anti-PVRIG antibody and COM902, a potential
best-in-class antibody targeting TIGIT for the treatment of solid
tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the
TIGIT component is derived from Compugen's clinical stage
anti-TIGIT antibody, COM902, is in Phase 3 development by
AstraZeneca through a license agreement for the development of
bispecific and multispecific antibodies. In addition, the
Company's therapeutic pipeline of early-stage immuno-oncology
programs consists of programs aiming to address various mechanisms
of immune resistance, of which the most advanced program, COM503, a
potential first-in-class, high affinity anti-IL-18 binding protein
antibody, which has been granted IND clearance from the FDA, is
licensed to Gilead. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Company contact:
Yvonne Naughton, Ph.D.
VP, Head of Investor Relations, and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-release-third-quarter-2024-financial-results-on-tuesday-november-12-2024-302289893.html
SOURCE Compugen Ltd.